Esperoct
Drug
Novo Nordisk AS
Total Payments
$2.4M
Transactions
1,287
Doctors
264
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $313,982 | 158 | 90 |
| 2023 | $713,452 | 72 | 32 |
| 2022 | $269,722 | 204 | 80 |
| 2021 | $480,199 | 294 | 67 |
| 2020 | $647,876 | 555 | 63 |
| 2019 | $349.04 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.9M | 669 | 78.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $390,416 | 121 | 16.1% |
| Consulting Fee | $84,200 | 44 | 3.5% |
| Travel and Lodging | $48,154 | 105 | 2.0% |
| Food and Beverage | $10,388 | 318 | 0.4% |
| Education | $968.10 | 30 | 0.0% |
Payments by Type
Research
$1.9M
669 transactions
General
$534,126
618 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NN7088-3908 | Novo Nordisk AS | $502,525 | 0 |
| CBB WO_21 | Novo Nordisk AS | $424,970 | 0 |
| NN7088-4410 | Novo Nordisk AS | $407,202 | 0 |
| NN7088 and NN7999 | Novo Nordisk AS | $291,929 | 0 |
| NN7088 & NN7999 | Novo Nordisk AS | $122,311 | 0 |
| work order for the production of an enzyme at CBB | Novo Nordisk Inc | $103,510 | 0 |
| NN7088-3859 | Novo Nordisk AS | $31,178 | 0 |
| NN7088-4928 | Novo Nordisk Inc | $4,730 | 0 |
| NN7088-4928 | Novo Nordisk AS | $3,100 | 0 |
Top Doctors Receiving Payments for Esperoct
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Juan, PR | $1.9M | 669 |
| , MD | Pediatric Hematology-Oncology | Slidell, LA | $86,073 | 46 |
| , M.D | Pediatrics | Orlando, FL | $66,027 | 29 |
| , M.D | Hematology | Los Angeles, CA | $49,483 | 28 |
| , MD | Pediatric Hematology-Oncology | Charleston, SC | $38,214 | 32 |
| , MD | Pediatrics | Nashville, TN | $35,343 | 26 |
| , M.D | Pediatrics | Las Vegas, NV | $30,922 | 17 |
| Richard Lemons | Pediatric Hematology-Oncology | Salt Lake City, UT | $30,683 | 22 |
| , NP-C | Pediatrics | Sacramento, CA | $29,834 | 24 |
| Dennis Borrero Ramos | Pediatrics | Orlando, FL | $26,283 | 17 |
| , M.D | Internal Medicine | Memphis, TN | $21,612 | 13 |
| , MD | Hematology & Oncology | Louisville, KY | $18,900 | 7 |
| , M.D | Internal Medicine | Houston, TX | $14,310 | 5 |
| , M.D | Pediatric Hematology-Oncology | Los Angeles, CA | $9,800 | 8 |
| , M.D | Pediatric Hematology-Oncology | San Juan, PR | $9,003 | 4 |
| , MD | Pediatrics | Detroit, MI | $8,370 | 3 |
| , M.D | Pediatrics | Charlotte, NC | $8,039 | 5 |
| , M.D., J.D | Family Medicine | Schaumburg, IL | $5,325 | 3 |
| , MD | Pediatric Hematology-Oncology | Redlands, CA | $4,500 | 3 |
| , ARNP | Registered Nurse | Miami, FL | $4,470 | 7 |
| , MD | Pediatric Hematology-Oncology | Aurora, CO | $4,050 | 1 |
| , MD | Pediatrics | Miami, FL | $4,029 | 3 |
| , M.D | Pediatrics | Peoria, IL | $3,400 | 2 |
| , M.D | Pediatrics | Chicago, IL | $3,080 | 2 |
| , MD | Hematology | Iowa City, IA | $2,975 | 2 |
Ad
Manufacturing Companies
- Novo Nordisk AS $1.8M
- Novo Nordisk Inc $626,641
- Novo Nordisk Health Care AG $15,725
Product Information
- Type Drug
- Total Payments $2.4M
- Total Doctors 264
- Transactions 1,287
About Esperoct
Esperoct is a drug associated with $2.4M in payments to 264 healthcare providers, recorded across 1,287 transactions in the CMS Open Payments database. The primary manufacturer is Novo Nordisk AS.
Payment data is available from 2019 to 2024. In 2024, $313,982 was paid across 158 transactions to 90 doctors.
The most common payment nature for Esperoct is "Unspecified" ($1.9M, 78.0% of total).
Esperoct is associated with 9 research studies, including "NN7088-3908" ($502,525).